Pliant Therapeutics (PLRX) Stock Price, Quote, News & History | Benzinga

Pliant Therapeutics Inc (PLRX) Stock Price, Quote, News & History

PLRXNASDAQ

Trade with Public

Trade with Public

$1.05

N/A

At close: Aug 7, 5:00 PM EST

$1.05

N/A

After Hours: Aug 6, 4:21 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$1.05

Close

$1.05

Volume / Avg.

310.41K / 520.72K

Day Range

$1.03 - $1.07

52 Wk Range

1.03 - 1.95

Market Cap

$65.02M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

43

Short Interest

4.66%

Days to Cover

3.27

Recent Pliant Therapeutics, Inc. News

Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors

Pliant Therapeutics posts interim Phase 1 data showing antitumor activity and durable responses for PLN-101095 in ICI-refractory advanced cancer patients.

Vandana Singh

Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types

Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested in its Phase 1 trial.

Vandana Singh

Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future

Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited catalysts and pipeline challenges.

Vandana Singh

This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Avi Kapoor

Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder

Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The company plans further data analysis.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-98.70M

Investing Cash Flow (TTM)

61.08M

Financing Cash Flow (TTM)

-32.12M

Free Cash Flow (TTM)

-98.81M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-69.75M

Analyst Trends and Forecast

1

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

2.3

Sell

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$77.09M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

0.39

Earnings Yield % (TTM)

-174.29%

Earnings Yield % (FWD)

-135.24%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.67

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$22.19M

Debt to Equity

0.17

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$1.05

Close

$1.05

Volume / Avg.

310.41K / 520.72K

Day Range

$1.03 - $1.07

52 Wk Range

1.03 - 1.95

Market Cap

$65.02M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

43

Short Interest

4.66%

Days to Cover

3.27

About

Sector

Health Care

Industry

Pharmaceuticals

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-b...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Pliant Therapeutics (PLRX) stock?

A

You can purchase shares of Pliant Therapeutics (NASDAQ:PLRX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Pliant Therapeutics (PLRX) competitors?

A

Other companies in Pliant Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Pliant Therapeutics (PLRX) stock?

A

Pliant Therapeutics has a consensus price target of $8.69.

Q

What is the current price for Pliant Therapeutics (PLRX)?

A

The stock price for Pliant Therapeutics (NASDAQ: PLRX) is $1.05 last updated August 6, 2026 at 4:21 PM EDT.

Q

Does Pliant Therapeutics (PLRX) pay a dividend?

A

There are no upcoming dividends for Pliant Therapeutics.

Q

When is Pliant Therapeutics (NASDAQ:PLRX) reporting earnings?

A

Pliant Therapeutics does not have any upcoming earnings scheduled.

Q

Is Pliant Therapeutics (PLRX) going to split?

A

There is no upcoming split for Pliant Therapeutics.

Q

What sector and industry does Pliant Therapeutics (PLRX) operate in?

A

Pliant Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.